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Cyclin-dependent kinases (CDKs) are involved in temporal control of the cell cycle and transcription and play
central roles in cancer development andmetastasis. Recently, Kwiatkowski and colleagues identified a novel
CDK7-specific inhibitor, THZ1, that hinders proliferation in cancer cell lines and dampens global transcription
in T cell leukemia.In eukaryotes, RNA polymerase II (Pol II)-
catalyzed transcription is facilitated by
general transcription factors (GTFs) con-
sisting of TFIIA, TFIIB, TFIID, TFIIE, TFIIF,
and TFIIH (Sims et al., 2004; Thomas and
Chiang, 2006). Transcription initiation
starts with recognition of the core pro-
moter by the TBP subunit of the TFIID
complex, followed by TFIIB entering and
stabilizing the TFIID-promoter interaction.
Following these initial events, Pol II enters
the complex and is stabilized by TFIIF
action. Subsequently, TFIIE enters and
recruits TFIIH to the promoter, facilitating
the formation of the preinitiation complex
and the transition from transcription initia-
tion to early elongation. GTFs such as
TFIID and TFIIH are misregulated or
mutated inmultiple cancer types (Bywater
et al., 2013), contributing to an altered
regulation of transcription levels in malig-
nant cells. Thus, drugs directly targeting
the basic transcription machinery could
potentially be applied to inhibit tumor
growth; however, the development of
such therapeutic approaches has been
challenging.
The general transcription factor TFIIH
purified from mammalian cells consists
of ten subunits, seven of which (p62,
p52, p44, p34, XPD, XPB, and TTDA)
form the core complex. Three subunits
(cyclin H, MAT1, and CDK7) form the cy-
clin-activating kinase subcomplex (CAK),
which is linked to TFIIH’s core via the
XPD (ATP-dependent helicase) subunit
of the complex. During the process of
transcription initiation, the helicase activ-
ity of TFIIH opens the core promoter
DNA, while CDK7 phosphorylates the
C-terminal domain (CTD) of Pol II at serine
5 and 7 (Akhtar et al., 2009) as well as
other transcription factors controlling the158 Cancer Cell 26, August 11, 2014 ª2014 Einitiation-to-elongation transition (Laro-
chelle et al., 2012). Due to the deregu-
lation of CDKs in malignancies, they are
potential targets of antitumor drugs; how-
ever, most of the CDK inhibitors target
the highly conserved kinase domain and
could inhibit multiple CDK family mem-
bers (Ali et al., 2009). Thus, the identifica-
tion of more selective and potent CDK
inhibitors is imperative for the develop-
ment of effective cancer therapies.
In their recent study, Kwiatkowski et al.
(2014) identified a CDK7 inhibitor called
THZ1, which was effective at low concen-
trations in reducing the proliferation of
a number of cancer cell lines, including
human T cell lymphoblastic leukemia
(T-ALL) (Figure 1). THZ1 has an acryl-
amidemoiety that can react with cysteine,
suggesting that this could be the first
covalent inhibitor of a CDK. Indeed, a
modified analog of THZ1 that cannot
react with cysteine failed to inhibit
CDK7. Although a kinome-wide profiling
assay revealed that THZ1 was able to
inhibit other kinases, only the inhibition
of CDK7 activity could be achieved at
lower THZ1 doses if incubated for longer
periods of time, consistent with the irre-
versible nature of covalent bonds.
Furthermore, incubation of a biotinylated
form of THZ1 with CDK7, followed by
western blotting with an anti-biotin anti-
body, demonstrated a highly stable inter-
action. Mass spectrometry analysis of
the THZ1-treated CAK complex demon-
strated that THZ1 targeted cysteine 312
(C312) of CDK7, consistent with THZ1’s
docking model and CDK7’s crystal struc-
ture. Unlike most CDK inhibitors identified
before, the THZ1 targeting site on CDK7
lies outside the kinase domain, providing
possible explanations for the specificitylsevier Inc.of inhibition. Furthermore, THZ1 failed to
inhibit the phosphorylation of Pol II by
C312S mutant CDK7 in an in vitro kinase
assay, corroborating results that C312
covalently links CDK7 to THZ1. It would
be important to further explore potential
off-target effects of THZ1 by testing if
overexpressing C312S CDK7 could
rescue the growth inhibition of cancer
cells caused by THZ1.
CDK7 deletion in mouse embryonic
fibroblasts does not lead to a global
decrease of Ser5 phosphorylation,
possibly due to compensation by remain-
ing CDKs (Ganuza et al., 2012). Mean-
while, Kwiatkowski and colleagues
demonstrated that THZ1 treatment of
Jurkat cells led to the loss of phosphory-
lation on Ser 2, 5, and 7 of CTD. This sug-
gests that either THZ1 could inhibit the
activity of other CDKs, leading to the
loss of all three forms of CTD phosphory-
lation in cells, or the enzyme responsible
for implementation of these marks require
CDK7 activity. To address these possibil-
ities, Kwiatkowski and colleagues found
that THZ1 could also inhibit CDK12
activity, albeit at higher concentrations
compared with CDK7, perhaps because
the nearest cysteine in CDK12 is three
amino acids away from the equivalent
position of CDK7 C312. Because CDK12
was not identified by the kinome-wide
profiling assays as a THZ1 target, it is
essential to include a search for other
proteins interacting with THZ1 to further
study its in vivo activity, such as incu-
bating biotinylated THZ1 with cellular
extracts, followed by streptavidin pull-
downs and mass spectrometry to identify
interacting proteins.
Kwiatkowski and colleagues next









Figure 1. THZ1 Inhibits the CDK7 Kinase
Activity, Pol II CTD Phosphorylation, and
Global Transcription in Cancer Cells
IIH, TFIIH; P, phosphorylation.
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types and found potent antiproliferation
in a good proportion of cell lines, indi-
cating the broad cancer-inhibitory effect
of THZ1. THZ1 treatment of animals
injected with T-ALL cells led to a sig-
nificant inhibition of tumor growth
compared with control animals, while it
had minimal effects on animal weight.
Kwiatkowski and colleagues further
demonstrated that the potent antipro-
liferation effect was possibly due to the
induction of apoptosis in cancer cells by
THZ1. To understand the gene regulatory
mechanisms of THZ1, Kwiatkowski and
colleagues analyzed gene expression
changes in Jurkat cells upon treatment
of THZ1 and demonstrated that THZ1
caused global mRNA downregulation in
cells. Interestingly, THZ1 reduced Pol II
occupancy at promoters and gene bodies
in Jurkat cells, unlike the gene body effect
of the known CDK inhibitor flavopiridol
(Senderowicz, 2002). RUNX1, TAL1, and
GATA3 form a feed-forward autoregula-
tory loop in T-ALL cells, maintaining an
oncogenic transcription program. Kwiat-
kowski and colleagues found that theRUNX1 gene was particularly sensitive
to low doses of THZ1 in Jurkat cells and
suggested that the cluster of enhancers
regulating RUNX1 expression was
responsible for the sensitivity to THZ1.
Enhancers and factors regulating their ac-
tivities have been shown to be central in
cellular development, and their misregu-
lation in cancer is becoming a major sub-
ject of study (Herz et al., 2014). Remark-
ably, transcripts downregulated by THZ1
showed a significant overlap with genes
downregulated upon RUNX1 knockdown,
suggesting that THZ1 led to transcrip-
tional changes in Jurkat cells through re-
pressing RUNX1 and the transcription cir-
cuit in T-ALL cells. Further investigations
on whether RUNX1 overexpression could
restore the global transcription decrease
caused by THZ1 will be important to
clarify the mechanisms of tumor suppres-
sion by THZ1.
Taken together, the work of Kwiatkow-
ski and colleagues provides the charac-
terization of a CDK7 inhibitor, THZ1, and
the mechanistic explanation for its potent
antiproliferative effects on cancer cells.
Unlike previously identified CDK inhibi-
tors, THZ1 covalently binds to CDK7
outside of the kinase domain, suggesting
a novel approach for designing small
molecules to target specific factors in
cancer therapies. Importantly, the tumor
suppression effects observed for THZ1
may be due to the transcriptional regula-
tion of a small group of critical genes,
indicating the potential efficacy of target-
ing transcription machinery in cancer
therapies. Therefore, these findings sug-
gest that cell- and gene-specific effects
can be observed even when targeting a
so called ‘‘general transcription factor.’’
It would be interesting to explore the
transcriptional and growth effects of
THZ1 on cancer cell lines and in animal
models in addition to T-ALL cells. ToCancer Cell 26further characterize the mechanisms and
effects of THZ1 on tumor suppression,
detailed comparison studies between
THZ1 and other known CDK inhibitors
such as the well-studied CDK inhibitor
flavopiridol and the CDK7-specific inhibi-
tor BS-181 could also be very informative.ACKNOWLEDGMENTS
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